Evaluation of state opioid substitution treatment program in Georgia.
Evaluation of State Opioid Substitution Treatment OST (methadone and buprenorphine/naloxone- Addnok-N) program in Georgia and optimization of the routine measurement instrument. Patients were recruited from 4 Tbilisi and 5 regional State Programs in May-October 2013. 2 structured self-questionnaires (one - anonymous for sensitive questions) were developed for patients to assess demographics, retention in treatment, mean drug dose, HIV and Hepatitis C and B status, illicit drug and alcohol use, social activities, crime involvement, health status, HIV risk behavior, treatment compliance and satisfaction. 608 patients (7 females) were surveyed (512 - on Methadone, 96 - on buprenorphine/naloxone). 337 (1 female) patients completed an anonymous questionnaire. Mean age - 39.43±8.7 (21-65 years). 10 (1.64%) respondents were HIV positive; 448 (73.68%) - HCV+ and 24 (3.95%) - HBV+; average methadone dose - 39.27±22.2mg; buprenorphine/naloxone - 7.4±3.6 mg; 64 (40%) of employed began working while in program; 365 (60%) have been in treatment for less than 1 year, and 146 (24%) - for 1-3 years vs. 258 (51%) out of 506 patients surveyed in 2011. 494 (81.2%) reported improvement of social status and 508 (83.5%) - of health status. 305 (90.5%) out of 337 reported no- and 30 (8.9%) - reduction of criminal activity. 467 (76.81%) patients attended individual and 200 (32.9%)-group psychotherapy sessions with various frequencies. The common adverse events: sleep disturbances - 48.84%; weakness - 50.82%; mood disturbances - 42.44%, and heaviness - 36.35%. 257 (46%) reported using of alcohol; 16 - opioids; 29 - sedative/hypnotics; 8 - marijuana and 1 - ATS past 30 days; 55 - drug injection and 11 - sharing of any injection equipment past 6 months. State OST program is effective in Georgia in terms of reduction of illegal drug use, injection risk behavior and criminal activity, and on the other hand - improving of social activity and general health. Treatment retention is less as compared with 2011 survey.
Center for Mental Health and Prevention of Addiction, Tbilisi, Georgia.
G
G
Piralishvili
Center for Mental Health and Prevention of Addiction, Tbilisi, Georgia.
M
M
Chavchanidze
Center for Mental Health and Prevention of Addiction, Tbilisi, Georgia.
I
I
Gamkrelidze
Center for Mental Health and Prevention of Addiction, Tbilisi, Georgia.
N
N
Nikolaishvili
D000328:Adult; D000368:Aged; D000437:Alcoholism; D002047:Buprenorphine / Q000627:therapeutic use*; D005260:Female; D005846:Georgia (Republic); D006078:Government Programs; D015658:HIV Infections; D006509:Hepatitis B; D006526:Hepatitis C; D006801:Humans; D008297:Male; D008691:Methadone / Q000627:therapeutic use*; D008875:Middle Aged; D009270:Naloxone / Q000627:therapeutic use*; D058850:Opiate Substitution Treatment / Q000379:methods*; D010349:Patient Compliance; D017060:Patient Satisfaction; D011795:Surveys and Questionnaires; D055815:Young Adult
D009270:Naloxone; D002047:Buprenorphine; D008691:Methadone